Unfit sufferers even have the alternative of venetoclax plus obinutuzumab (VO) as frontline therapy. This relies with a stage III demo that compared VO with ClbO in elderly/unfit people.113 VO was top-quality regarding reaction price and development-free survival, and experienced a equivalent security profile.For more choices, take a look at our ne… Read More